Uday Kompella's Laboratory
Uday B. Kompella, Ph.D. Uday Kompella, Ph.D.
Associate Professor
 Departments of Pharmaceutical Sciences & Opthalmology
 985840 Nebraska Medical Center
 Omaha, NE 68198-5840, USA
 Tel: (402) 559-2974
 Fax:(402) 559-5368
  E-mail: ukompell@unmc.edu
Education | Academic Appointments | Grants | Patents | Awards | Bibliography | Presentations | Professional Service | Academic Activities |

EDUCATION

PhD (Pharm. Sci.) - University of Southern California, Los Angeles, USA.

M.Pharm (Pharm. Engg.) - Jadavpur University, Calcutta, India.

B.Pharm (Hons) - Birla Institute of Technology and Science, Pilani, India.

ACADEMIC APPOINTMENTS

07/01 - present Associate Professor, Department of Pharmaceutical Sciences, UNMC College of Pharmacy, University of Nebraska Medical Center (UNMC), Omaha, NE. (tenured)

07/02 – present Associate Professor, Department of Ophthalmology, UNMC, Omaha, NE (Courtesy faculty appointment)

07/98 - 07/01 Assistant Professor, Department of Pharmaceutical Sciences, UNMC College of Pharmacy, Omaha, NE.

09/94 - 06/98 Assistant Professor, Department of Pharmacal Sciences, School of Pharmacy, Auburn University, Auburn, AL.

OTHER APPOINTMENTS

07/05 - present Chair, Pharmaceutical Sciences Graduate Program, UNMC, Omaha, NE

07/05 – present Member, Center for Drug Delivery and Nanomedicine, UNMC, Omaha, NE

07/04 - present Member, Biomedical Engineering Research Initiative & Graduate Program, University of Nebraska System

09/98-present Graduate Faculty Member and Graduate Faculty Fellow, UNMC, Omaha, NE

09/98-present Associate Member, Cancer Center, UNMC, Omaha, NE

04/94-08/94 Research Scientist, Balance Pharmaceuticals, Inc., Los Angeles, California

08/90-12/93 Research Assistant, University of Southern California, Los Angeles, CA

08/89-07/90 Teaching Assistant, University of Southern California, Los Angeles, CA

03/89-07/89 Medical Representative, Merind Limited, Bombay, India

[Top]

GRANT/CONTRACT SUPPORT

Grants Funded (Role: Principal Investigator)

  • Corneal and scleral permeability of drugs. Ophtha Technical Development, Novartis AG, Basel. [01/05-12/05].
  • Anti-VEGF and antiproliferative effects of novel drugs. Novacea, Inc. [07/01/04-06/30/05].
  • Biocompatibility of SABER formulations in the eye. Durect Corporation. [07/01/04-06/30/05].
  • Equipment for supercritical fluid processes. Nebraska Banker’s Association. [06/01/04-05/31/05].
  • Pharmacological approaches to treat diabetic retinopathy – minority supplement (R01 DK064172-S1). National Institutes of Health, Bethesda, MD. [04/03-03/07].
  • Pharmacological approaches to treat diabetic retinopathy (R01 DK064172). National Institutes of Health, Bethesda, MD. [04/03-03/06].
  • Subconjunctival route to prolong corticosteroid delivery (R03 EY013842). National Institutes of Health (NEI), Bethesda, MD. [08/01/03-07/31/06].
  • Ocular drug disposition from novel Alcon formulations. Alcon Research, Ltd., Fort Worth, TX. [12/11/03-12/11/04].
  • Ocular drug delivery research. Santen Corporation, Japan. [2002-present]. Unrestricted funding.
  • Retinal delivery of celecoxib to inhibit VEGF expression. UNMC seed grant.  [2001].
  • Inhibition of VEGF expression and angiogenesis. Controlled Delivery Systems, Inc., Watertown, MA. [04/01 - 01/02].
  • Deslorelin transport across bovine nasal tissue. Balance Pharmaceuticals, Inc., Santa Monica, CA. 1[02/00 - 11/02].
  • Assessment of bovine nasal tissue for peptide drug transport: A feasibility study with deslorelin. Balance Pharmaceuticals, Inc., Santa Monica, CA. [08/00 - 07/01].
  • Mechanisms and kinetics of degradation of deslorelin in nasal epithelial cells. Balance Pharmaceuticals, Inc., Santa Monica, CA. [03/00 - 02/01].
  • Ocular absorption of levobetaxolol from novel formulations - 1. Alcon Laboratories, Inc., Fort Worth, TX. [10/98 -10/00].
  • AAPS new investigator grant in pharmaceutics, drug delivery and pharmaceutical technology. Unrestricted research funding. [08/98 - 07/00].
  • Ocular absorption of levobetaxolol. Alcon Laboratories, Inc., Fort Worth, TX. [08/98 - indefinite].
  • Systemic and ocular absorption of novel ARIs (R15 EY1177-03). National Institutes of Health (NEI), Bethesda, MD. [03/97 - 02/00]. (Co-investigators: Jack DeRuiter and C. Randall Clark).
  • Production of budesonide particles for pulmonary delivery using supercritical fluid antisolvent precipitation technique.Auburn University Biogrant Proposal, Auburn University, Auburn, AL. [12/97 - 11/99]. (Co-investigator. Christopher B. Roberts, Department of Chemical Engineering).
  • Ocular absorption of drugs from Alcon formulations. Alcon Laboratories, Inc., Fort Worth, TX. [07/97 - 06/98].
  • A preliminary bioequivalence study of phenylbutazone paste in horses. Med-Pharmex, Inc., Pomona, CA. [04/97 - 08/97]. (Co-investigators: William R. Ravis, Ram Purohit, Sue H. Duran).
  • Mechanisms of transport of dideoxyinosine across cornea and conjunctiva. Future Life Science Scholars Program. Sponsored by Howard Hughes Institute through a core grant to Auburn University. [06/97 - 09/97]. (Role: Mentor for James Kelly, a high school student from Opelika).
  • A sustained release device for deslorelin in treating cystic ovarian disease in cattle. Future Life Science Scholars Program. Sponsored by Howard Hughes Institute through a core grant to Auburn University. [06/97 - 9/97]. (Role: Mentor for Sharon Williams, a student from Tuskegee University).
  • Fabrication and characterization of porous biodegradable membranes. DPD Inc., 2000 Turner St., Lansing, MI. [08/96 - 10/96].
  • Fabrication and characterization of porous biodegradable membranes. Future Life Science Scholars Program. Sponsored by Howard Hughes Institute through a core grant to Auburn University. [06/96 - 9/96]. (Role: Mentor for a college student).
  • ELISA analysis of deslorelin in rabbit plasma samples. Balance Pharmaceuticals, Inc., 842 Las Casas Ave., Pacific Palisades, CA.[10/95 - 12/95].
  • Ocular Absorption of drugs from ten formulations; Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, TX. [08/95 - 7/97].
  • Influence of an anti-glaucoma agent on rabbit corneal and conjunctival ion transport; Sigma Xi Headquarters, 99 Alexander Drive- Box 13975, Research Triangle Park, NC.[03/95 - 2/96].
  • Deslorelin: HPLC assay and nasal degradation (Role: Mentor for Megan Huff of Opelika). Future Life Science Scholars Program at Auburn University; Sponsored by Howard Hughes Institute. [06/95 - 8/95].
  • Development and characterization of an in vitro model for drug and ion transport across rabbit nasal epithelial tissue. Auburn University Research Grant-in-Aid. [05/95 - 04/96].
  • RIA and ELISA analysis of estradiol, testosterone, and deslorelin in human serum samples. Balance Pharmaceuticals, Inc., 842 Las Casas Ave., Pacific Palisades, CA. [03/95 - ].
  • RIA and ELISA analysis of estradiol, testosterone, and deslorelin in rabbit plasma samples. Balance Pharmaceuticals, Inc., 842 Las Casas Ave., Pacific Palisades, CA. [03/95 - ].
  • RIA and ELISA analysis of estradiol, testosterone, and deslorelin in rabbit plasma samples. Balance Pharmaceuticals, Inc., 842 Las Casas Ave., Pacific Palisades, CA. [02/95 - ].

    • Grants Funded (Role: Co-investigator)

  • Pharmacokinetics of nonsteroidal anti-inflammatory drugs in South American Camelids. Morris Animal Foundation, 45 Inverness Drive East, Englewood, CO 80112. [11/97-10/98]. ( PI: Christine Navarre).
  • Assessment of self-learning ability: Validation of scales and outcome measures. Auburn University Research Grant-in-Aid proposal. [10/97]. (PI: Debbie C. Byrd).
  • Novel GnRH agonist therapy for cystic ovaries in cattle. USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL. [10/97 - 09/98]. ( PI: James G.W. Wenzel).
  • Corneal and conjunctival transport of novel aldose-reductase inhibitors. Future Life Science Scholars Program. Sponsored by Howard Hughes Institute through a core grant to Auburn University. [6/97-9/97]. [Role: Co-advised (along with Jack DeRuiter) Erika Thomas, a high school student from Mississippi].
  • A novel LHRH agonist therapy for cystic ovaries in cattle. USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL. [10/96-9/97]. ( PI: James Wenzel).
  • Development of a nasally administered vaccine to combat Pasteurella haemolytica in cattle. USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL. [10/96-9/97]. (PI: Sue Hudson Duran).
  • Regional administration of ceftiofur for the treatment of septic foot conditions in cattle. USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL. [10/95-9/96]. (PI: Christine B. Navarre).
  • Development of a nasally administered vaccine to combat Pasteurella haemolytica in cattle. USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL.[10/95-9/96]. (PI: Sue Hudson Duran).

    [Top]

    PATENTS/INVENTION DISCLOSURES
     

  • Compounds to inhibit cellular release of VEGF. Invention disclosure submitted to UNMC during June 1999.

  • Methods and compositions to sustain retinal/ocular drug delivery. Invention disclosure submitted to UNMC during July 2001.

  • Compounds to inhibit cellular release of VEGF. Invention disclosure submitted to UNMC during July 2001.

  • Approaches to elevate retinal delivery of drugs. Invention disclosure submitted to UNMC during July 2001.

    HONORS AND AWARDS
     

  • 2005 Fellow, American Association of Pharmaceutical Scientists. Recognition as a distinguished contributor and acknowledged leader in the advancement of pharmaceutical sciences.

  • 2005 Recognition Award, Regulatory Sciences Section, American Association of Pharmaceutical Scientists

  •  2003 Distinguished Teaching Award, University of Nebraska Medical Center, Omaha, NE.

  • 2002 Award of Appreciation by Graduate Students - In recognition of contributions and support as a faculty advisor. XXXIV Annual Pharmaceutics Graduate Research Meeting (June 13-15, 2002). Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE.

  • 1997-98 Alumni Undergraduate Teaching Excellence Award, Auburn University

  • 1997 Recipient of AAPS new investigator grant in pharmaceutics, drug delivery and pharmaceutical technology for 1997. Sponsored by Pfizer Central Research

  • 1997 Recognition Award. American Association of Indian Pharmaceutical Scientists

  • 1996 Who's Who in Science and Engineering, The Marquis Who's Who Publication Board.

  • 1995 Full member, Sigma Xi, The Scientific Research Society

  • 1994 Outstanding Achievement, Office of International Students, University of Southern California, Los Angeles, CA

  • 1993 Student Assistantship from Genentech, Inc. to attend Western Regional AAPS meeting held at San Francisco, CA

  • 1992 Outstanding paper in pharmacokinetics, pharmacodynamics, drug metabolism, and clinical sciences (PPDM & CS) section of AAPS meeting held at San Antonio, sponsored by Eli Lilly & Co.

  • 1992 Best poster award in the graduate student research forum (GSRF) at University of Southern California, sponsored by Doheney Eye Institute, Los Angeles, CA.

  • 1987-89 Fellowship from University Grants Commission, New Delhi, India

  • 1983-87 National Merit Scholarship, India

ELECTED OFFICES

  1. Chair, Regulatory Sciences Section, American Association of Pharmaceutical Scientists, 2003-2004.
  2. Chair-Elect, Regulatory Sciences Section, American Association of Pharmaceutical Scientists, 2002-03.
  3. Chair, Ocular Drug Delivery and Disposition Focus Group, American Association of Pharmaceutical Scientists. 2001-2003.
  4. Vice Chair, Regulatory Sciences Section, American Association of Pharmaceutical Scientists, 2001-02.
  5. Secretary, Ocular Drug Delivery and Disposition Focus Group, American Association of Pharmaceutical Scientists. 1999-2001.
  6. Secretary/Treasurer, Regulatory Affairs Section, American Association of Pharmaceutical Scientists. 1998-01.

[Top]

Publications

  1. Margalit, E., Kugler, L.J., Brum, M.V., Meza, J.L., Kompella, U.B., Escobar, E., and Christensen, G.R. The safety of intraocular ketorolac in rabbits. Invest. Ophthalmol. Vis. Sci. (in press).

  2. Yun, M., Smyth, H., Kompella, U.B.* Particle engineering for sustained pulmonary drug delivery. Business Briefings: Drug Delivery 2006. (in press).

  3. Amrite, A., Ayalasomayajula, S.P., Cheruvu, N.P.S., Kompella, U.B.* Single periocular injection of celecoxib-PLGA microparticles reduces diabetes induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47(3):1149-1160 (2006).

  4. Hammond, M. and Kompella, U.B.* Nanotechnology and nanoparticles: Clinical, ethical, and regulatory issues. In: Nanoparticle Technology for Drug Delivery. Ram B. Gupta and Uday B. Kompella (Eds.). Marcel Dekker, Inc. New York. Pp. 381-395 (2006).

  5. Amrite, A. and Kompella, U.B.* Nanoparticles for ocular drug delivery. In: Nanoparticle Technologies for Drug Delivery. Ram B. Gupta and Uday B. Kompella (Eds.). Marcel Dekker, Inc. New York (in press).

  6. Amrite, A. and Kompella, U.B.* Disposition of periocularly administered nanoparticles and microparticles. J. Pharm. Pharmacol. 57(12):1553-1563 (2005).

  7. Bandi, N., Ayalasomayajula, S.P., Iwakawa, J., Cheng, P-W, and Kompella, U.B.* Intratracheal budesonide microparticles sustain respiratory delivery of budesonide and reduce oxidative stress, VEGF expression and vascular leakage in a benzo(a)pyrene-fed mouse model for lung tumors. J. Pharm. Pharmacol. 57(7):851-860 (2005).

  8. Dhanda, D.S. and Kompella, U.B. * Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs) for Pulmonary Drug Delivery: CMC Issues. Clin. Res. Reg. Affairs 22(1):31-55 (2005).

  9. Dhanda, D.S., Leopold, D., Frey II, W.H., and Kompella, U.B.* Approaches for the deposition of drugs in the human olfactory epithelium. Drug Del. Technol. 5(4)64-72 (2005).

  10. Ayalasomayajula, S. P. and Kompella, U. B.* Subconjunctival administration of celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 511:493-498 (2005).

  11. Kompella, U.B.* Graduate education in the era of nanotechnology, nanomedicine, and pharmacogenomics. Controlled Release Society News Letter, 22(1):22-32 (2005).

  12. Raghava, S., Hammond, M., and Kompella, U.B.* Periocular routes for retinal drug delivery. Exp. Opinion Drug Del. 1:99-114 (2004).

  13. Ayalsomayajula, S.P. and Kompella, U.B. * Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm. Res. 21(10):1797-1804 (2004).

  14. Sundaram, S., Bontha, S. S., and Kompella, U.B.* Respiratory delivery of deslorelin, a peptide drug. Am. Pharm. Rev. 7(5):130-139 (2004).

  15. Bandi, N., Wei, W., Roberts, C.B., Kotra, L.P., and Kompella, U.B.* Preparation of budesonide- and indomethacin- hydroxypropyl-ß-cyclodextrin (HPßCD) complexes using an organic-solvent-free, single-step supercritical fluid process. Eur. J. Pharm. Sci. 23(2): 159-168 (2004).

  16. Ayalasomayajula, S.P., Amrite, A., and Kompella, U.B.* Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin-E2 secretion from diabetic rat retinas. Eur. J. Pharmacol. 498:275-278 (2004).

  17. Koushik, K., Dhada, D.S., Cheruvu, N.P.S., and Kompella, U.B.* Pulmonary delivery of deslorelin: Large porous PLGA particles and HPCD complexes. Pharm. Res. 21(7):1119-1126 (2004).

  18. Koushik, K. and Kompella, U.B.* Transport of deslirelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. J. Pharm. Pharmacol. 56(7):861-868 (2004).

  19. Amrite, A.A., Cheruvu, N.P.S., Sundaram, S., Aravalli, R.N., Cheng, P-W, and Kompella, U.B.* Lung Gene Therapy: Clinical and Regulatory Issues. Clin. Res. Reg. Affairs 21:1-28 (2004).

  20. Koushik, K., Bandi, N., and Kompella, U.B.* Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm. Res. 21:1034-1046 (2004).

  21. Sunkara, G., Ayalasomayajula, S.P., Cheruku, R.S., Vennerstrom, J.L., DeRuiter, J., and Kompella, U.B.* Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J. Pharm. Pharmacol. 56:351-358 (2004).

  22. Koushik, K. and Kompella, U.B.* Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical CO2 process. Pharm Res. 21:524-535 (2004).

  23. Koushik, K. and Kompella, U.B. * Particle and device engineering for inhalation drug delivery. Drug Del. Technol. 4: 40-50 (2004).

  24. Amrite, A. and Kompella, U.B.* Eye cancers. xPharm (2004). Executive editors: S.J. Enna and David B. Bylund; Elsevier Inc., New York. http://www.xpharm.com/citation?Article ID=913 (Online peer-reviewed disease and pharmacology database).

  25. Ha, E., Ganguly, M., Li, X., Jasti, B.R., and Kompella, U.B.* Delivery of peptide and protein drugs. In: Theory and Practice of Contemporary Pharmaceutics, Tapash K. Ghosh and Bhaskara R. Jasti (Eds.), Taylor & Francis, pp. 525-547 (2004).

  26. Mayo, A. and Kompella, U.B. * Supercritical fluid technology in pharmaceutical research. In: Encyclopedia of Pharmaceutical Technology. James Swarbrick (Ed.). Marcek Dekker, Inc., New York, pp, 1-17, 2004.

  27. Bandi, N., Gupta, R.B., Roberts, C.B., and Kompella, U.B.* Formulation of controlled release drug delivery systems. In: Drug Delivery and Supercritical Fluid Technology. Marcel Dekker, Inc. P.York, U.B. Kompella, and B. Shekunov (Eds). Marcel Dekker, Inc., New York. 367-410, 2004.

  28. Kompella, U.B.* Reflections of Uday B. Kompella, PhD, Student Chapter Faculty Advisor. AAPS Newsmagazine. Page 41, July 2004.

  29. Aukunuru, J.V., Ayalasomayajula, S.P., and Kompella, U.B.* A nanoparticle formulation enhances the delivery and activity of a VEGF antisense oligonucleotide in human retinal pigment epithelial (ARPE-19) cells. J. Pharm. Pharmacol. 55(9):1199-1206 (2003).

  30. Cheruvu, N.P.S., Ayalasomayajula, S.P., and Kompella, U.B.* Retinal delivery of sodium fluorescein, budesonide, and celecoxib following subconjunctival injection. Drug Del. Technol. 3(6): 62-67(2003).

  31. Amrite, A. and Kompella, U.B.* Ocular distribution of intact nano- and microparticles following subconjunctival and systemic routes of administration. Drug Del. Tech. 3:62-67 (2003).

  32. Koushik, K., Sunkara, S., Gwilt, P., and Kompella, U.B.* Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharm. Res. 20:779-787 (2003).

  33. Kompella, U.B.*, Bandi, N., and Ayalasomayajula, S.P. Subconjunctival nano- and micro-particles for sustained retinal delivery of budesonide, a glucocorticoid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 44: 1192-1201 (2003).

  34. Ayalasomayajula, S.P. and Kompella, U.B.* Celecoxib, a selective COX-2 inhibitor, inhibits retinal VEGF expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur. J. Pharmacol. 458:283-289 (2003).

  35. Sunkara, G. and Kompella, U.B.* Membrane transport processes in the eye. In: Ocular Drug Delivery Systems. Mitra A.K. (Ed.), Marcel Dekker, Inc. 2nd Edition, pp 13-58, 2003.

  36. Wenzel, J.G.W., Sree Balaji, K.S., Koushik, K., Navarre, C., Duran, S.H., Rahe, C.H., and Kompella, U.B.* Pluronic® F127 gel formulation of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J. Control. Rel. 85:51-59 (2002).

  37. Zhang, L., Parsons, D.L., Navarre, C.B., and Kompella, U.B.* Development and in vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J. Control. Rel. 85:73-81 (2002).

  38. Martin, T.M., Bandi, N., Schulz, R., Roberts, C., and Kompella, U.B. Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSciTech. 3(3) article 18 (2002).

  39. Ayalasomayajula, S.P. and Kompella, U.B.* Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur. J. Pharmacol. 449:213-220 (2002).

  40. Bandi, N. and Kompella, U.B.* Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (calu-1). Eur. J. Pharmacol. 437(2): 9-17 (2002).

  41. Sunkara G. and Kompella, U.B.* Drug delivery applications of supercritical fluid technology. Drug Del. Technol. 2:44-50 (2002).

  42. Aukunuru, J.V. and Kompella, U.B.* In vitro delivery of nano- and micro-particles to retinal pigment epithelial (RPE) cells. Drug Del. Technol. 2:50-57 (2002).

  43. Aukunuru, J.V., Sunkara, G., Ayalasomayajula, S.P., DeRuiter, J., Clark, R.C., and Kompella, U.B.* A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm. Res. 19:278-285 (2002).

  44. Koushik, K.N., Bandi, N., and Kompella, U.B.* Interaction of [D-Trp6-Des-Gly10]LHRH ethylamide and hydroxypropyl b-cyclodextrin (HPbCD): Thermodynamics of interaction and protection from degradation by a-chymotrypsin. Pharm. Dev. Technol. 6:595-606 (2001).

  45. Kompella, U.B.*, Bandi, N., and Ayalasomayajula, S.P. Poly(lactic acid) nanoparticles for sustained release of budesonide. Drug Del. Technol. 1(1), 28-34(2001).

  46. Bandi, N. and Kompella, U.B.* Budesonide reduces vascular endothelial growth factor (VEGF) secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur. J. Pharmacol. 425:109-116 (2001).

  47. Aukunru, J.V. and Kompella, U.B.* Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm. Res. 18:565-572 (2001).

  48. Kompella, U.B.* and Koushik, K. Preparation of drug delivery systems using supercritical fluid technology. Crit. Rev. Ther. Drug Carr. Syst. 18:173-199 (2001).

  49. Kompella, U.B. and Lee, V.H.L. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations, Adv. Drug Del. Rev. 46:211-245 (2001).

  50. Sunkara, G. and Kompella, U.B.* Controlled Release of Bioactive Materials – 28th International Symposium. Carbohydrate drug carriers: Cyclodextrins and chitosans. IDrugs, 4(9):1014-1016 (2001).

  51. Sunkara, G., DeRuiter, J., Clark, C.R., and Kompella, U.B.* In-vitro hydrolysis, permeability, and ocular uptake of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor intended for ocular complications of diabetes. J. Pharm. Pharmacol. 52:1113-1122 (2000).

  52. Aukunuru, J.V., Kompella, U.B., and Betageri, G.V. Simultaneous high-performance liquid chromatographic analysis of acetaminophen, salicylamide, phenyltoloxamine and related products. J. Liq. Chrom. & Rel. Technol. 23:565-578 (2000).

  53. Kompella, U.B.*, Sunkara, G., Thomas, E., Clark, C.R., and DeRuiter, J. Corneal and Conjunctival Permeability of Novel Aldose Reductase Inhibitors: N-[[4-(Benzoylamino)phenyl]sulfonyl]glycines and N-Benzoyl-N-phenyl Glycines. J. Pharm. Pharmacol. 51:921-927 (1999).

  54. Sunkara, G., Navarre, C.B., and Kompella, U.B.* Influence of pH and temperature on kinetics of ceftiofur degradation in aqueous solutions. J. Pharm. Pharmacol. 51:249-255 (1999).

  55. Navarre, C.B., Zhang, L., Sunkara, G., Duran, S.H., and Kompella, U.B. Ceftiofur distribution in plasma and joint fluid following regional limb injection in cattle. J. Vet. Pharmacol. Ther. 22:13-19 (1999).

  56. Kompella, U.B.*, Aukunuru, J.V., and Betageri, G.V. Effect of neutral liposomes on corneal and conjunctival transport of didanosine. Drug Delivery 6:9-14 (1999).

  57. Ayalasomayajula, S.P. and Kompella, U.B.* Drug efflux pumps: Challenges and opportunities. 14-18 November 1999, New Orleans, USA. American Association of Pharmaceutical Scientists - Annual Meeting and Exposition (Part IV). IDrugs 3(2):148-149 (2000).

  58. Koushik, K. and Kompella, U.B.* Particle engineering and modeling techniques for inhalation delivery. 14-18 November 1999, New Orleans, USA. American Association of Pharmaceutical Scientists - Annual Meeting and Exposition (Part V). Investigational Drugs Weekly Highlights, 49:44-46 (1999).

  59. Aukunuru, J.V. and Kompella, U.B.* American Association of Pharmaceutical Scientists - Annual Meeting and Exposition (Part VI). Recent advances in particulate and implant drug delivery systems. 14-18 November 1999, New Orleans, USA. Investigational Drugs Weekly Highlights, 49:58-61 (1999).

  60. Kompella, U.B.* Protein drug delivery. In: Biopharmaceutical Drug Design and Development, Wu-Pong, S. and Rojanasakul, Y. (Eds.), Humana Press, pp. 239-274, 1999.

  61. Kompella, U.B. and Lee, V.H.L. Barriers to drug transport in ocular epithelia, in: Transport Processes in Pharmaceutical Systems. G.L. Amidon, P.I. Lee, and and E.M. Topp (eds.) Marcel Dekker, Inc., New York, pp. 317-376, 1999.

  62. Kompella, U.B.* "Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development, Mathiowitz, E.,Chickering, D.E., III, and Lehr, C-M. (eds), Marcel Dekker, Inc., New York, 1999". Review for Doody Publishing Company (1999). Book-review.

  63. Mathison, S., Nagilla, R., and Kompella, U.B.* Nasal route for direct delivery of solutes to brain. Fact or Fiction? J. Drug Targeting 5:415-441(1998).

  64.  Kompella, U.B.*, Katragadda, A.K., Aukunuru, J.V., and Betageri, G.V. Effect of liposomal charge on stavudine transport across cornea and conjunctiva. Pharm. Pharmacol. Commun. 4:339-343 (1998).

  65. Dani, B.A. and Kompella, U.B.* Inhibition of corneal metabolism of deslorelin by EDTA and ZnCl2, Drug Dev. Ind. Pharm. 24(1):11-17 (1998).

  66. Kompella, U.B.* Drug delivery applications of supercritical fluid technology. 15-19 November 1998, San Francisco, USA. American Association of Pharmaceutical Scientists Annual Meeting and Exposition (Part II). IDrugs, 2(1):33-34 (1999).

  67. Kompella, U.B.* Disposition of non-viral gene delivery systems and oligonucleotides. 15-19 November 1998, San Francisco, USA. American Association of Pharmaceutical Scientists Annual Meeting and Exposition (Part V). IDrugs, 2(1):31-32 (1999).

  68. Kompella, U.B.* and Dani, B.A. Metabolism of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbit conjunctiva, J. Ocular Pharmacol. Ther. 13(2):163-170 (1997).

  69. Kompella, U.B.* and Dani, B.A. Metabolism of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbit nasal tissue, Life Sci., 58:2201-2207 (1996).

  70. Kompella, U.B., Kim, K.J., Shiue, M.H.I., and Lee, V.H.L., Cyclic AMP modulation of active ion transport in the pigmented rabbit conjunctiva, J. Ocular Pharmacol. Ther. 12:281-287 (1996).

  71. Hosoya, K., Kompella, U.B., Kim, K.J., and Lee, V.H.L., Contribution of Na+-glucose cotransport to the short-circuit current in the pigmented rabbit conjunctiva, Curr. Eye Res. 15:447-451 (1996).

  72. Kompella, U.B., Kim, K.J., and Lee, V.H.L., Possible existence of Na+-coupled amino acid transport in the pigmented rabbit conjunctiva, Life Sci. 57:1427-1431 (1995).

  73. Kompella, U.B., Kim, K.J., and Lee, V.H.L. Active secretion of chloride across the pigmented rabbit conjunctiva, Curr. Eye Res. 12:1041-1048 (1993).

  74. Lee, Y.H., Kompella, U.B., and Lee, V.H.L. Systemic absorption pathways of topically applied beta-adrenergic antagonists in the pigmented rabbit, Exp. Eye Res. 57:341-349 (1993).

  75. Kompella, U.B. and Lee, V.H.L. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations, Adv. Drug Del. Rev. 8:115-162 (1992).

  76. Lee, V.H.L. and Kompella, U.B., “Therapeutic Monoclonal Antibodies, Borrebaeck, C.A.K. and Larrick, J.W., Stockton Press, New York, 1990”, J. Control. Rel., 18:280-281 (1992). Book-review.

  77. Lee, V.H.L., Yamamoto, A., and Kompella, U.B., Mucosal penetration enhancers for facilitation of peptide and protein drug absorption, CRC Crit. Rev. Drug Carrier Sys. 8:91-192 (1991).

  78. Kompella, U.B. and Lee, V.H.L. Pharmacokinetics of peptide and protein drugs, in: Peptide and Protein Drug Delivery, V.H.L. Lee (ed.), Marcel Dekker, Inc., New York, pp. 391-484, 1991.

  79. Nagappa, A.N., Kompella, U.B., Shankar, S., Mitra, S., and Srivastava, R.C., Liquid membrane phenomenon in the biological action of gonadal steroid hormones, Ind. J. Biochem & Biophys. 25:350-355 (1988).

Conference Proceedings (Peer-reviewed)

  1. Koushik, K., Bandi, N., Sunkara, G., and Kompella, U.B.* Respiratory delivery of a peptide drug: degradation pathways, transport mechanisms, and sustained release large porous microparticles prepared using supercritical fluid technology. Proceed. Int. Symp. Contr. Rel. Bioact. Mat., 30: (2003).

  2. Sunkara, G., Aukunuru, J. V., DeRuiter, J., Clark, C.R., and Kompella, U.B.* Ocular delivery of a novel aldose reductase inhibitor. Chemical, biological, and delivery system approaches. Proceed. Int. Symp. Contr. Rel. Bioact. Mat. 28:251-252 (2001).

  3. Kompella, U.B., Kim, K.J., and Lee V.H.L., Paracellular permeability of a chloride secreting epithelium, Proceed. Int. Symp. Contr. Rel. Bioact. Mat. 19:522-523 (1992).

  4. Kompella, U.B. and Lee V.H.L. Influence of dosing time on systemic insulin absorption from eye drops, Proceed. Int. Symp. Contr. Rel. Bioact. Mat. 18:599-600 (1991).

Books Edited 

  1. Supercritical Fluid Technology in Pharmaceutical Product Development. Peter York, Uday B. Kompella, and Boris Shekunov (eds.), Volume 138 in Drugs and Pharmaceutical Sciences, 666 pages, Marcel Dekker, Inc. (2004).

  2. Nanoparticle Technologies for Drug Delivery. Ram B. Gupta and Uday B. Kompella (eds.), Volume 159 in Drugs and Pharmaceutical Sciences, 403 pages, Marcel Dekker, Inc. (2006).

Published Course Materials 

  1. Dondeti, P. and Kompella, U.B. Supercritical fluid technology in drug delivery research. A two-day seminar series. Zurich Hilton Hotel, Zurich, Switzerland, April 10-11, 1997. Sponsored and published by Technomic Publishing AG. (50% responsibility).

  2. Kompella U.B. and Ravis W.R., Pharmaceutics III. Biopharmaceutics and Pharmackokinetics, Kinko Copies, 1995, 1996, 1997.

Editorials

  1. Tammara, V. and Kompella, U.B. Editorial. Clin. Res. Reg. Affairs 21(1): 2004.

  2. Tammara V. and Kompella, U.B. Implantable microchip approval, flu vaccine shortage, and Vioxx® withdrawal. Clin. Res. Reg. Affairs 21(1): 2004. 

Peer-reviewed Journals Edited 

  1. Editor, Clinical Research and Regulatory Affairs. A journal published by Marcel Dekker, Inc. (2004-present).

  2. Editor, Expert Reviews. Pharmaceutical Research (December 2004 – present). Recruited several new authors in emerging scientific areas. Executing peer-review process for Pharm. Res. articles.

Audiovisual Educational Material 

  1. Lectures in Biopharmaceutics and Pharmacokinetics (PY 401). Videotapes of lectures intended for students in transition at Auburn University.

[Top]

INVITED PRESENTATIONS

  1. Particles 2006, Orlando, FL. Particulate systems for pulmonary drug delivery: Sustained release, efficacy, and safety. May 13-16, 2006.
  2. Drug Delivery 2006. Pharmaceutical Education Associates Conference, San Diego. Retinal drug delivery. May 17-19, 2006.
  3. Shankara Netralaya, Chennai, India. Nanotechnology for drug and gene delivery to the eye. March 10, 2006.
  4. Shankara Netralaya, Chennai, India. Ophthalmic applications of nanotechnology. March 3, 2006.
  5. Birla Institute of Technology, Mesra, India. Ophthalmic applications of nanotechnology. February 27, 2006.
  6. Calcutta University, Kolkata, India. Ophthalmic applications of nanotechnology. February 23, 2006.
  7. Birla Institute of Technology and Science, Pilani, India. Particle engineering for pulmonary drug delivery. February 21, 2006.
  8. Birla Institute of Technology and Science, Pilani, India. Ophthalmic applications of nanotechnology. February 20, 2006.
  9. NIPER-NANO 2006, Chandigarh, India. Ophthalmic applications of nanotechnology. Nanotechnology Conference. February 17-18, 2006.
  10. University of Florida Symposium on Medical Applications of Nanotechnology. Nanoparticles for drug delivery to the anterior and posterior segments of the eye. December 8, 2005.
  11. University of Wisconsin, College of Pharmacy. Retinal delivery of drugs capable of inhibiting VEGF expression. November 4, 2005.
  12. Leo Pharma, Copenhagen, Denmark. 1) Retinal delivery of drugs capable of inhibiting VEGF expression. 2) Overview of retinal drug delivery. October 19-20, 2005.
  13. Kansas State University, Department of Biochemistry, Sustained retinal delivery of drugs capable of inhibiting VEGF expression. October 5, 2005.
  14. Drug Delivery & Deal Making Summit, New Brunswick, NJ. Transscleral drug delivery to the retina. September 26-28, 2005.
  15. IVT Conference on Drug Delivery Systems, San Francisco. Sustained drug delivery to the lungs. September 22, 2005.
  16. Glaucoma Foundation’s 12th Think Tank Meeting (Integrating Nanotechnology and Drug Delivery for Neuroprotection), New York, NY. Nanotechnology for drug delivery to the anterior segment. September 15-17, 2005.
  17. Aciont Inc., Salt Lake City, UT. 1) Retinal delivery of drugs capable of inhibiting VEGF expression. 2) Overview of retinal drug delivery. August 8-9, 2005.
  18. Purdue University, Department of Industrial and Physical Pharmacy, West Lafayette, IN. Retinal delivery of drugs capable of inhibiting VEGF expression. July 28, 2005.
  19. UNMC Department of Ophthalmology, Gifford Lecture Series. Nanotechnology for ophthalmic applications. June 10, 2005.
  20. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL. Special topic session on nanotechnology applied to ophthalmology. Nanotechnology for anterior and posterior segment drug delivery. May 2, 2005.
  21. IDEXX Pharmaceuticals, Inc., Greensboro, NC. Ocular drug delivery. January 17, 2005.
  22. Iomed, Inc., Salt Lake City, UT. Transscleral approaches for retinal drug delivery. January 4, 2005.
  23. Merck & Co., West Point, PA. 1) Transscleral approaches for retinal drug delivery (seminar and round table). 2) Overview of retinal drug delivery (seminar). December 14, 2004.
  24. Indiana University, School of Optometry, Bloomington, IN. Sustained retinal drug delivery. November 19, 2004.
  25. Glaucoma Foundation’s 11th Think Tank Meeting (Optic Nerve Rescue and Restoration), New York, NY. Microparticles and nanoparticles for anterior segment drug delivery. September 9, 2004.
  26. Glaucoma Foundation Think Tank Meeting (Optic Nerve Rescue and Restoration), New York, NY. Subconjunctival drug delivery. September 9, 2004.
  27. University of Otago, Dunedin, NZ. Supercritical fluid technology for respiratory drug delivery systems. September 6, 2004.
  28. International Congress for Eye Research, Sydney, Australia. Sustained retinal delivery of drugs capable of inhibiting VEGF expression. August 31, 2004.
  29. Bausch & Lomb, Rochester, NY. Drug delivery to the anterior and posterior segments of the eye. July 9, 2004.
  30. AAPS Pharmaceutics and Drug Delivery Conference, Philadelphia, PA. Role of multidrug resistance associated protein in retinal drug delivery. June 7, 2004.
  31. Ethicon (Johnson & Johnson), NJ. Nanoparticles and microparticles for drug delivery. May 28, 2004.
  32. University of Nebraska Medical Center, Omaha, NE. Presentation at the Second Annual Scholars Day. Career opportunities in pharmaceutical sciences. March 2004.
  33. Barnett International Nasal Drug Delivery Workshop, Philadelphia. Nasal delivery of deslorelin, a peptide drug. February 27, 2004.
  34. Indian Pharmaceutical Congress. Chennai, India. Supercritical fluid technology for respiratory drug delivery systems. December 20, 2003.
  35. Al-Ameen College of Pharmacy, Bangalore, India. Subconjunctival route for sustained retinal delivery of drugs capable of inhibiting VEG expression. December 18, 2003.
  36. Inspire Pharmaceuticals, Inc., Durham, NC. Drug delivery to the eye. December 3, 2003.
  37. Durect Corporation, Cupertino, CA. Drug delivery to the back of the eye. November 3, 2003.
  38. University of Nebraska Medical Center, Omaha, NE. Presentation at the First Annual Scholars Day. Career opportunities in pharmaceutical sciences. March 21, 2003.
  39. Novartis Ophthalmics, Atlanta, GA. Drug delivery to the back of the eye. January 22, 2002.
  40. UNMC Department of Ophthalmology, Gifford Lecture Series. Chemical, biological, and delivery system approaches for the ocular delivery of a novel aldose reductase inhibitor. May 11, 2001.
  41. Santen Co. at ARVO. Subconjunctival and sub-tenon particulate systems for drug delivery to the retina. May 3, 2001.
  42. Santen Co. at ARVO. An in situ perfusion technique to assess blood-retinal barrier permeability. May 3, 2001.
  43. University of Nebraska Medical Center, Department of Pharmacology, Omaha, NE. Ocular delivery of novel aldose reductase inhibitors. October 22, 1999.
  44. University of Missouri - Kansas City, Department of Pharmaceutical Sciences, Kansas City, MO. Transport processes in ocular and respiratory epithelia. August 26, 1999.
  45. University of Nebraska Medical Center, Department of Ophthalmology. Drug and ion transport across ocular epithelia. January, 1999.
  46. Fine Particle Society’s 28th Annual Meeting, Dallas, TX. Conference on pharmaceutical science and technology. Symposium on delivery systems for proteins, vaccines and oligonucleotides. Nasal delivery of macromolecules and vaccines. April 3, 1998.
  47. Alcon Laboratories, Inc., Fort Worth, TX. Corneal and conjunctival transport of liposomal deoxynucleosides., April 1, 1998.
  48. Pfizer Central Research, Groton, CT. Epithelial ion transport modulation to enhance hydrophilic drug transport. March 27, 1998.
  49. University of Nebraska Medical Center, Omaha, NE. Modulation of ion transport pathways to enhance drug delivery. Janyary 4, 1998.
  50. University of Cincinnati, Cincinnati, OH. Ion and drug transport in the conjunctiva. December 15, 1997.
  51. Technomic Publishing AG Seminar Series, Zurich Hilton Hotel, Zurich, Switzerland. Fundamentals of supercritical fluid technology (solubility parameters). April 10, 1997.
  52. Technomic Publishing AG Seminar Series, Zurich Hilton Hotel, Zurich, Switzerland. Supercritical fluid technology in peptide and protein drug delivery. April 10, 1997.
  53. Technomic Publishing AG Seminar Series, Zurich Hilton Hotel, Zurich, Switzerland. Application of supercritical fluid technology in controlled release dosage forms. April 11, 1997.
  54. Technomic Publishing AG Seminar Series, Zurich Hilton Hotel, Zurich, Switzerland. Other pharmaceutical application of supercritical fluid technology: Drug analysis, drug extraction, and polymer processing. April 11, 1997.
  55. Alcon Laboratories, Inc., Fort Worth, TX. Use of ion transport processes in modulating ocular drug transport. March 20, 1997.
  56. Duquesne University, School of Pharmacy, Pittsburgh, PA, Systemic delivery of a peptide drug: Systemic uptake and nasal metabolism. February 13, 1997.
  57. Auburn University, Repro Forum, Auburn, AL. Delivery of an LHRH agonist across mucosal tissues. January 28, 1997.
  58. Med-Pharmex, Inc., Pomona, CA. Ceftiofur regional therapy for foot infection in cattle. December 21, 1996.
  59. Balance Pharmaceuticals, Inc., Santa Monica, CA. Nasal delivery of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbits. December 20, 1996.
  60. Auburn University School of Pharmacy, Auburn, AL. Presentation at Group Learning Workshop. Peer group methods in teaching pharmacokinetics. July 1, 1996.
  61. Bayer Corporation, Berkeley, CA. Nasal delivery of [des-Gly10, D-Trp6]LHRH ethylamide. June 28, 1996.
  62. Northeast Louisiana University, School of Pharmacy, Monroe, LA. Drug transport in the rabbit cornea. March 1996.
  63. Auburn University, School of Pharmacy, Auburn, AL. Ion and drug transport processes in the pigmented rabbit conjunctiva. March 1994.
  64. Northeastern University, School of Pharmacy, Boston, MA, Ion and drug transport processes in the pigmented rabbit conjunctiva. May 1993.
  65. Agouron Pharmaceuticals, Inc., San Diego, CA. Drug transport in the pigmented rabbit conjunctiva: Modulation by ion transport. May 1993.
  66. West Coast Salt and Water Club Meeting, Morro Bay, Active ion transport in the rabbit conjunctiva: Mechanisms and modulation, 1993.
  67. University of Southern California, Cellular and Molecular Physiology Journal Club. Mechanisms of drug transport in the pigmented rabbit conjunctiva, 1993.
  68. University of Southern California, Los Angeles, Cellular and Molecular Physiology Journal Club. Mechanisms of ion transport in the pigmented rabbit conjunctiva, 1992.
  69. American Association of Pharmaceutical Sciences, Graduate Symposium in PPDM and CS section of AAPS, San Antonio, Mechanisms of active ion transport in the pigmented rabbit conjunctiva, 1992.

[Top]

STUDENT AND RESEARCH TRAINEES

 Graduate Student Committees 

PhD Students (Role: Supervisor/Advisor/Chairman of the Advisory Committee) 

Students Mentored, Recognitions, and Employment 

  1. Gangadhar Sunkara (1998-2002). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Transport, pharmacokinetics, and ocular delivery of N-4-((benzoylamino)phenylsulfonyl)glycine, an aldose reductase inhibitor. Graduated with a PhD in January 2002.
    1. AAPS graduate symposium award in pharmaceutics and drug delivery, sponsored by Procter & Gamble, 2001.
    2. First position for his podium presentation during GRASP meeting held at Kansas City during 1999.
    3. UNMC fellowship, 1999-2002.
    4. Founding editor, Focus newsletter, Ocular drug delivery & disposition focus group of AAPS.
    5. Chair, the UNMC AAPS Student Chapter.
    6. Employment: Clinical Pharmacokineticist,  Novartis, New Jersey (first & current job).
  2. Jithan V. Aukunuru (1998-2002). Department of Pharmaceutical Sciences, UNMC College of Pharmacy.  Retinal delivery of an aldose reductase inhibitor and a VEGF antisense oligonucleotide. Graduated with a PhD in March 2002.
    1. AAPS graduate symposium award in pharmaceutics and drug delivery, sponsored by Procter & Gamble, 2000.
    2. UNMC Fellowship, 2000-2002.
    3. Employment: Scientist, Novartis Ophthalmics, Atlanta, GA (first job). Scientist, Ranbaxy Laboratories, Ltd., Delhi, India (current job).
  3. Bandi Nagesh (1998-2003). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Respiratory delivery of budesonide in a mouse model for lung tumors. Graduated in August, 2003.
    1. AAPS graduate symposium award in biotechnology, sponsored by G.D. Searle, 2000.
    2. UNMC fellowship, 2001-2003.
    3. Harris award in cancer-related research in graduate studies, UNMC, 2003.
    4. Chair, the UNMC AAPS Student Chapter.
    5. Employment: Senior Formulation Scientist, GlaxoSmithkline, New Jersey (first job); Senior Research Investigator, Sanofi Aventis (current job).
  4. Kavitha Koushik (1998-2004). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Repiratory delivery of deslorein, a potent LHRH agonist. Graduated in February 2004.
    1. AAPS graduate symposium award in pharmaceutics and drug delivery, sponsored by Procter & Gamble, 2002.
    2. Award for best college of pharmacy presentation at the Midwest Student Biomedical Research Forum, Omaha, 2003.
    3. Second position award for her podium presentation during GRASP meeting held at University of Illinois, Chicago, 2003.
    4. UNMC fellowship, 2000-2003.
    5. Employment: Formulation Scientist at Barr Pharmaceuticals, Inc., New York (first & current job).
  5. Surya Prakash Ayalasomayajula (1999-2004). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Retinal delivery of drugs capable of inhibiting VEGF expression. Graduated in May 2004.
    1. AAPS graduate symposium award in pharmaceutics and drug delivery sponsored by BMS, 2003.
    2. UNMC fellowship, 2001-2004.
    3. Bukey fellowship, 2000.
    4. Recipient of Research to Prevent Blindness Travel award, 2002 annual ARVO meeting, Fort Lauderdale, FL.
    5. Chair, the UNMC AAPS Student Chapter, 2003-2004.
    6. Employment: Clinical Pharmacokineticist at MDS Pharma Services, Lincoln, NE (first job). Clinical Pharmacokineticist, Novartis, NJ (current job).

PhD Students Continuing (Role: Supervisor/Advisor; Chairman of the Advisory Committee) 

  1. Narayan Cheruvu (2002-present). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Transscleral drug delivery.
    1. Recipient of UNMC graduate fellowship, January 2003-2006.
    2. Internship, Alza Corporation, June 2004 – October 2004.
  2. Aniruddha Amrite (2002-present). Department of Pharmaceutical Sciences. UNMC College of Pharmacy. Drug and gene delivery for retinal degenerative disorders.
    1. Overall first place award for oral presentation in the 2005 Midwest Biomedical Research Forum.
    2. UNMC first place for oral presentation in the 2005 Midwest Biomedical Research Forum.
    3. UNMC College of Pharmacy first place for oral presentation in the 2005 Midwest Biomedical Research Forum.
    4. UNMC graduate fellowship, 2003-2004; 2004-present.
    5. Chair, the UNMC AAPS Student Chapter, 2005-2006.
    6. Acting Chair, the UNMC AAPS Student Chapter, 2005.
  3. Devender Dhanda (2003- present). Department of Pharmaceutical Sciences. UNMC College of Pharmacy. Drug Delivery for Lung Cancer Therapy.
    1. Recipient of the American Heart Association Graduate Fellowship (2004-2006).
  4. Sneha Sundaram (2003-present). Department of Pharmaceutical Sciences. UNMC College of Pharmacy. LHRH receptor mediated drug delivery for cancer therapy.
  5. Swita Raghava (2004-present). Department of Pharmaceutical Sciences. UNMC College of Pharmacy. Ocular Drug Delivery.
    1. Recipient of the UNMC Graduate Fellowship 2004-2005.
    2. Secretary, the UNMC AAPS Student Chapter, 2004-2005.
  6. Aaron Mayo (2004-present). Department of Pharmaceutical Sciences. UNMC College of Pharmacy. Respiratory Drug Delivery.
    1. Recipient of overall 4th place award for oral presentation in the Midwest Biomedical Research Forum, 2005.
    2. Vice Chair, the UNMC AAPS Student Chapter, 2004-2005.

MS Students (Role: Supervisor/Advisor; Chairman of the Advisory Committee) 

  1. Bhas A. Dani (1994-1996). Department of Pharmacal Sciences, Auburn University. Metabolism of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbit nasal tissue: A comparison with cornea and conjunctiva. Graduated in 1996 from Auburn University.
    1. Recognized for being among the top ten graduates students with respect to course and research performance at Auburn University (graduate students from the entire campus and all disciplines were considered for this recognition).
    2. Sigma Xi scientific research grant-in-aid award recipient.
    3. Mr. Dani obtained his PhD from the University of Kentucky.
    4. Employment: Inhale Therapeutics, CA (first job). Chiron Corporation (current job).
  2. K. Sankaran Sree Balaji (1996-1998). Department of Pharmacal Sciences, Auburn University. Formulation and evaluation of a sustained release dosage form of deslorelin. Graduated in 1998 from Auburn University.
    1. Employment: CEO of I – Link Systems, Seattle.
  3. Kalyan S. Nuguru (1996-present). Department of Pharmacal Sciences, Auburn University. Fabrication and characterization of porous biodegradable membranes.
    1. Employment: Seatrace Pharmaceuticals, AL (first job). E-Merck, NJ (current job).
  4. Lin Zhang (1997-1999). Department of Pharmacal Sciences, Auburn University. Regional delivery of ceftiofur in cattle. Graduated in 1999 from Auburn University.
    1. Employment: Hoffman-La Roche, NJ (first & current job).
  5. Jithan V. Aukunuru (1997-1998; Role: Co-chair). Department of Pharmacal Sciences, Auburn University.  Ocular delivery of liposomal ddI. Initially enrolled in MS. Mr. Aukunuru was transferred to the PhD program at Auburn. In July 1998, Mr. Aukunuru relocated to UNMC.
  6. Gangadhar Sunkara (1997-1998). Department of Pharmacal Sciences, Auburn University. Corneal and conjunctival transport and pharmacokinetics of aldose reductase inhibitors. In July 1998, Mr. Sunkara relocated to UNMC.
  7. Bandi Nagesh (1998). Department of Pharmacal Sciences, Auburn University. Delivery of macromolecules through the respiratory tract. In July 1998, Mr. Bandi relocated to UNMC.

Post-doctoral Fellows and Technicians (Role: Supervisor) 

  1. Rajagopal Aravalli, PhD (2004) Post-doctoral research associate. Role of COX-3 in the retina.
  2. Lin Zhou (2004), Post-doctoral research associate. Prodrugs for retinal delivery of drugs. Current Employment: UNMC College of Pharmacy (current).
  3. Pradip (2004-present), Post-doctoral research associate. Polymeric prodrugs for retinal and respiratory drug delivery.
  4. Mo Yun, PhD (2005- present). Post-doctoral research associate. Polymer and protein based nanomaterials for gene delivery to the eye and the respiratory tract.
  5. Ranjit Thakur, PhD (2006- present). Post-doctoral research associate. Preparation of gene delivery systems using supercritical fluid technology.
  6. Muhammed Subtbas, MD (2006 - present). Visiting Otolaryngology MD from Turkey. Sustained nasal drug delivery.
  7. Samuel Medaris, MD (2005 - present). UNMC Otolaryngology resident. VEGF inhibition for nasal polyposis.
  8. Ashley Robey (2005 - present). UNMC Otolaryngology medical student. Inhibitors of 5-LO for allergic rhinitis.
  9. Edith Rocio Bellido (2004-present), Research Technician.

College and High School Students (Role: Supervisor/Advisor) 

  1. Makena Hammond (Summer 2004, 2005). College student from University of Virginia, VA.
  2. Sneha Sundaram (Summer 2002). College student from Pittsburg State University, Pittsburg KS.
  3. Sharon Williams (~Summer 1998). Student from Tuskegee University. Project: “A sustained release device for deslorelin in treating cystic ovarian disease in cattle”. Auburn University Future Life Science Scholars Program sponsored by the Howard Hughes Institute. (100% responsibility)
  4. Candace Hodges (Summer 1996), Student from Stillman College, Tuscaloosa, AL. Project: Fabrication and characterization of porous biodegradable membranes. Auburn University Future Life Science Scholars Program sponsored by the Howard Hughes Institute. (100% responsibility)
  5. Grace Vanderpuije (1996). A visiting scholar (from Africa) at the Auburn University Department of Entomology. Project: Isolation and analysis of active ingredients from neem leaves and seeds.
  6. Anthony Gill (2004-present). Sacred Heart Elementary School, Omaha, NE.
  7. Ishod Kirksey (2003-2004). Sacred Heart Elementary School, Omaha, NE.
  8. Prentice Reddick (2001-2003). Sacred Heart Elementary School, Omaha, NE.
  9. Ahmad Johnson (1999-2001). Sacred Heart Elementary School, Omaha, NE.
  10. Warren Marion (1998-1999). Sacred Heart Elementary School, Omaha, NE.
  11. James Kelly (Summer 1997). High school student from Opelika. Project: “Mechanisms of transport of dideoxyinosine across cornea and conjunctiva”. Auburn University Future Life Science Scholars Program sponsored by the Howard Hughes Institute.
  12. Erika Thomas (~1996). High school student from Mississippi. Project: “Corneal and conjunctival transport of novel aldose-reductase inhibitors”. Erika was a bright student chosen by the Auburn University Future Life Science Scholars Program sponsored by the Howard Hughes Institute (50% responsibility).
  13. Megan Huff (Summer 1995). High school student from Opelika, AL. Project: HPLC assay and nasal metabolism of deslorelin. Auburn University Future Life Science Scholars Program sponsored by the Howard Hughes Institute.
  14. Jennifer Godinez (10/92-6/93). Magnet high school student from Los Angeles. Project: Evaluation of the secondary active transport processes in the rabbit conjunctiva STAR program student at the University of Southern California, Los Angeles, CA.

Other Advisory Roles 

PhD Committees (Role: Member of the Advisory Committee) 

  1. Michael Mulhern (2004-present). Department of Cell Biology & Genetics. UNMC College of Medicine. LEDGF for ER stress disorders.
  2. Sanjot Savant (2001-present). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Permeability of blood-brain-barrier.
  3. Yan Zhang (1998-2002). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. MRP expression in brain endothelial cells.
  4. Corbin Bachmeir (2000-present). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Novel substrates and inhibitors for MRP in brain endothelial cells.
  5. Todd Martin (1997-1998). Department of Chemical Engineering. Auburn University. Polymer phase behavior in supercritical fluids. Mr. Martin is currently pursuing his dissertation research.
  6. Sally Mathison (1997-1998). Department of Chemistry, Auburn University. Heparin transport across ion-selective membranes with application toward continuous direct heparin sensors and biocompatibility of ion-selective electrodes. Oral examination was successfully completed on 3/11/98.

MS Committees (Role: Member of the Advisory Committee) 

  1. Preeti Dochibhotla (2001-present). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Particulate Systems for Deslorelin and Taxol.
  2. Jasmine Davda (1998-2000). Department of Pharmaceutical Sciences, UNMC College of Pharmacy. Nanoparticulate Systems to Deliver VEGF.
  3. Aimee Kratina (1998-2001). Department of Pharmaceutical Sciences, UNMC College of Pharmacy.  Examination of BCECF-AM as a probe for drug efflux transporters. 09/30/99.
  4. Arun Kumar Katragadda (1996-1998). Department of Pharmacal Sciences, Auburn University.  Liposomal encapsulation, characterization, ocular delivery, and cellular uptake of stavudine. Graduated in 1998 from Auburn University.
  5. Cynthia Chang (1994-1996). Department of Pharmacal Sciences, Auburn University.  Percutaneous absorption enhancement of hydrocortisone. Graduated in 1996 from Auburn University.
  6. Babu N. Vutla (1994-1996). Department of Pharmacal Sciences, Auburn University. Liposomal formulation and transdermal iontophoretic delivery of the opioid peptide leucine enkephalin. Graduated in 1996 from Auburn University.
  7. Srikanth Kotha (1994-1998). Department of Fisheries and Aqua-culture, Auburn University. Optimization of the growth conditions of juvenile crayfish. 

Outside Reader (Ph.D. Students) 

  1. Nai-Zhen Wang (1994-1997). PhD in Biomedical Sciences, Department of Anatomy, Physiology & Pharmacology, College of Veterinary Medicine, Auburn University. Use of bioelastic membrane for percutaneous penetration of Dazmegrel, a selective thromboxane synthetase inhibitor. Graduated in 1997.
  2. Srikumar Sinnarajah (1993-1997). PhD in Biomedical Sciences, Department of Anatomy, Physiology & Pharmacology, College of Veterinary Medicine, Auburn University. Regulation of adenylyl cyclase by Gas/olf and Gai proteins in cilia of olfactory neurons. Oral examination held on 5/14/98. Graduated in 1998. 

Group Mentoring Activities 

  1. Faculty Advisor, AAPS UNMC-Student Chapter, 2002-present.
  2. Co-Advisor, Pharmaceutics Graduate Students Research Meeting, 2002.
  3. Advisor, Professional (Pharm.D.) Students (group of about 8 each year), UNMC College of Pharmacy. 1998-present.
  4. Mentor, Pharmacy Practice Experience, School of Pharmacy, Auburn University, 1997-1998. Supervision and evaluation of entry level Pharm.D. students in their service learning course.
  5. Mentor, Orientation of new students, School of Pharmacy, Auburn University, Fall 1996, Fall 1997. Responsibilities included training and monitoring two senior BS students in conducing a orientation case study and small group sessions.
  6. Mentor, PCS 351 (Pharmaceutical Care) patient interviews, School of Pharmacy, Auburn University, Fall 1996. The responsibilities included advising a group of 5 BS (03 level) students in preparing patient interview questions and generating written reports for two patient interviews.
  7. Chaperone, School of Pharmacy, Auburn University. Acted as a chaperone on a two-day excursion of undergraduate students to Eli Lilly & Company, Indianapolis, IN. 9/10/96-9/13/96.]

[Top]

SERVICE

Membership

  • 1990 - present     American Association of Pharmaceutical Scientists
  • 1990 - present     Association for Research in Vision and Ophthalmology
  • 1994 - present     American Association of Colleges of Pharmacy
  • 1995 - present     Sigma Xi, The Scientific Research Society
  • 1998 - present     Controlled Release Society
  • 2001 - present     American Diabetic Association

National Committees

  1. Member, 2007 Pharmaceutical Sciences World Congress Planning Committee, 2004-2007.

  2. Member, Paper screening committee, National Biotechnology Conference, 2006.

  3. Member, Newsmagazine sub-committee, American Association of Pharmaceutical Scientists. 2004-2005.

  4. Member, Portal sub-committee, American Association of Pharmaceutical Scientists. 2004-present.

  5. Member, Publications Committee, American Association of Pharmaceutical Scientists. 2003-2007. Nominated by the regulatory sciences section and selected by the AAPS executive council.

  6. Member, Scientific Advisory and Program Committee, Nasal Drug Delivery Focus Group, American Association of Pharmaceutical Scientists. 2002-present.

  7. Member, Nominations Committee, American Association of Pharmaceutical Scientists. 2004.

  8. Member, Themed Programming Committee, American Association of Pharmaceutical Scientists. 2003-2004.

  9. Member, Training Course Task Force, American Association of Pharmaceutical Scientists, 2003-2005.

  10. Member, Hot Topics Committee, American Association of Pharmaceutical Scientists. 2002-2003.

  11. Member, 2004 Program Co-ordination Committee, American Association of Pharmaceutical Scientists.

  12. Member, 2004 Injection Delivery Devices Workshop Planning Committee, American Association of Pharmaceutical Scientists.

  13. Member, RS Open Forum Planning Committee, American Association of Pharmaceutical Scientists. 2004.

  14. Member, 2004 National Biotechnology Conference Planning Commiittee, American Association of Pharmaceutical Scientists.

  15. Member, 2004 Pharmaceutics and Drug Delivery (PDD) Conference Planning Committee, American Association of Pharmaceutical Scientists.

  16. Editorial Board Member, Regulatory Sciences (RS) Newsletter, American Associat